_know-diabetes-by-heart-american-diabetes-associations-standards-of-care-in-diabetes2023-preview-1.jpg "Know Diabetes by Heart: American Diabetes Association’s Standards of Care in Diabetes—2023. from ada definition of diabetes Video Screenshot Preview 1")
Gallery_know-diabetes-by-heart-american-diabetes-associations-standards-of-care-in-diabetes2023-preview-3.jpg "Know Diabetes by Heart: American Diabetes Association’s Standards of Care in Diabetes—2023. from ada definition of diabetes Video Screenshot Preview 3")
Gallery_know-diabetes-by-heart-american-diabetes-associations-standards-of-care-in-diabetes2023-preview-hqdefault.jpg "Know Diabetes by Heart: American Diabetes Association’s Standards of Care in Diabetes—2023. from ada definition of diabetes Video Screenshot Preview hqdefault")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Jump To Video Parts
⏲ Duration: 58 minutes 55 seconds
👁 View: 7.9K times
Play Audio:👁 View: 7.9K times
Description:
American Diabetes Association
American Diabetes Association
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_decoding-the-ada-diabetes-mellitus-2023-guidelines-by-dr-karthik-vijaya-kumar.webp "DocTutorials Super Speciality")
⏲ 47 minutes 55 seconds 👁 18.4K
_ada-new-diabetes-screening-guidelines.webp "Armando Hasudungan")
_obesity-jabs-found-to-cut-risk-of-heart-attack-and-strokes.webp "Jabs designed to combat obesity might lower the likelihood of heart attacks, strokes, or heart failure among obese individuals, irrespective of the extent of weight loss experienced during the medication regimen. This indicates the potential for the treatment to yield benefits beyond mere reduction of excess body fat. Professor John Deanfield, who led the study, said the findings “have important clinical implications”. Report by Covellm. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn")
_american-diabetes-association-publishes-new-treatment-guidelines.webp "CBS New York")
_scientists-discover-hidden-indicator-of-future-weight-changes.webp "Scientists Discover , Hidden Indicator of Future , Weight Changes.<br/>'Newsweek' reports that scientists <br/>may have found a way to predict weight <br/>gain or loss from the size of fat cells. .<br/>Researchers from Sweden's Karolinska Institutet <br/>measured the size and number of fat cells <br/>in the abdominal fat of 260 volunteers. .<br/>The team found that after an average <br/>of 15 years, those with larger fat cells tended <br/>to lose weight, while those with smaller fat <br/>cells were more prone to gaining weight.<br/>We can only speculate as to <br/>why the size of a person's fat cells <br/>seems to predict their future weight, Peter Arner, a professor in the Department of Medicine <br/>at the Karolinska Institutet, via 'Newsweek'.<br/>Body weight decreases when energy <br/>expenditure exceeds intake and the <br/>body burns off fat to compensate. , Peter Arner, a professor in the Department of Medicine <br/>at the Karolinska Institutet, via 'Newsweek'.<br/>Our results suggest that the loss <br/>of large fat cells makes more <br/>of an impact on weight <br/>than the loss of small ones, Peter Arner, a professor in the Department of Medicine <br/>at the Karolinska Institutet, via 'Newsweek'.<br/>Peter Arner, one of the lead researchers on the study, <br/>notes that smaller fat cells have also been found <br/>to be linked to a better metabolic profile. .<br/>This means that if someone with <br/>small fat cells does gain weight, <br/>it may not raise their risk of <br/>conditions such as type 2 diabetes <br/>and high blood pressure as much <br/>as if they had large fat cells, Peter Arner, a professor in the Department of Medicine <br/>at the Karolinska Institutet, via 'Newsweek'.<br/>'Newsweek' reports that the team hope their <br/>findings will help develop more personalized weight <br/>management strategies for people in the future.<br/>It could be of great clinical <br/>value to have information <br/>about fat cell size before starting <br/>a weight-management program, Peter Arner, a professor in the Department of Medicine <br/>at the Karolinska Institutet, via 'Newsweek'.<br/>If it is the case that those with <br/>large fat cells find it easier to <br/>lose weight, those with smaller <br/>cells could be given extra support, Peter Arner, a professor in the Department of Medicine <br/>at the Karolinska Institutet, via 'Newsweek'")
_food-insecurity-and-diabetes-management-interventions-that-make-a-difference-quick-learn.webp "Centers for Disease Control and Prevention (CDC)")
⏲ 11 minutes 12 seconds 👁 726
_what-is-diabetes-124-2-minute-guide-124-diabetes-uk.webp "Diabetes UK")
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.webp "New Analysis Suggests , Long-Term Effectiveness , for Wegovy Users .<br/>NBC reports that patients taking <br/>Novo Nordisk's obesity treatment maintain <br/>an average of 10% weight loss over four years.<br/>The news potentially boosts the <br/>drugmaker's push for Wegovy to be <br/>covered by insurers and governments. .<br/>The company submitted long-term <br/>findings at the European Congress <br/>on Obesity in Venice, Italy. .<br/>This is the longest study <br/>we’ve conducted so far of <br/>semaglutide for weight loss, Martin Holst Lange, Novo’s head of development, via NBC.<br/>We see that once the majority <br/>of the weight loss is accrued, <br/>you don’t go back and start <br/>to increase in weight<br/>if you stay on the drug, Martin Holst Lange, Novo’s head of development, via NBC.<br/>According to another analysis published by <br/>the drugmaker, approximately 17% of trial participants stopped using the treatment <br/>due to side effects like nausea. .<br/>The costly treatment ranges from $200 <br/>to nearly $2,000 per month in the ten <br/>countries where the drug is available.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>NBC reports that Novo Nordisk was the <br/>first drugmaker to market GLP-1 agonists, <br/>originally developed as a diabetes treatment, <br/>to address record high obesity rates.<br/>Rival Eli Lilly launched its drug <br/>Zepbound in the United States <br/>in December of 2023. .<br/>Neither drugmaker has managed <br/>to produce enough of the <br/>treatment to meet surging demand")
_decoding-the-ada-diabetes-mellitus-2023-guidelines-by-dr-karthik-vijaya-kumar.jpg)
_ada-new-diabetes-screening-guidelines.jpg)
_obesity-jabs-found-to-cut-risk-of-heart-attack-and-strokes.jpg)
_american-diabetes-association-publishes-new-treatment-guidelines.jpg)
_scientists-discover-hidden-indicator-of-future-weight-changes.jpg)
_food-insecurity-and-diabetes-management-interventions-that-make-a-difference-quick-learn.jpg)
_what-is-diabetes-124-2-minute-guide-124-diabetes-uk.jpg)
_new-analysis-suggests-long-term-effectiveness-for-wegovy-users.jpg)
![[+]](/images/menu.gif){kind=small}